Nicox plans to advance a once-daily blepharitis treatment candidate for consideration for a phase 2b clinical trial, the company announced in a press release.
NCX 4251 0.1% administered either once daily (10 patients) or twice daily (10 patients) for 14 days reduced eyelid redness, eyelid debris and eyelid discomfort when compared with placebo in the Danube first-in-human trial.
The ophthalmic suspension of fluticasone propionate nanocrystals is under study for treatment of the eyelid margin in acute exacerbations of blepharitis. The treatment also “demonstrated promising efficacy”
Uncategorized